Search Results - "Roemeling, R V"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation by Doherty, N, Hancock, S L, Kaye, S, Coleman, C N, Shulman, L, Marquez, C, Mariscal, C, Rampling, R, Senan, S, Roemeling, R V

    “…Tirapazamine (SR 4233) is a benzotriazine di-N-oxide which acts as a hypoxic cytotoxic agent and as a radiation enhancer when given shortly before or after…”
    Get more information
    Journal Article
  2. 2

    Lack of antiemetic effect of high-dose metoclopramide by Roemeling, R V, Christiansen, N P, Hrushesky, W J

    Published in Journal of clinical oncology (01-09-1985)
    “…Sixteen of 26 patients given 51 courses of treatment of the doxorubicin and cisplatin combination with no antiemetic therapy suffered the same number of…”
    Get more information
    Journal Article
  3. 3

    High-dose intensity systemic therapy of metastatic bladder cancer by Hrushesky, W J, Roemeling, R V, Wood, P A, Langevin, T R, Lange, P, Farley, E

    Published in Journal of clinical oncology (01-03-1987)
    “…Forty-three consecutively diagnosed patients with widely metastatic transitional cell carcinoma of the bladder (TCCB) were treated with a high-dose intensity,…”
    Get more information
    Journal Article
  4. 4

    Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells by Tuchman, M, Roemeling, R V, Hrushesky, W A, Sothern, R B, O'Dea, R F

    Published in Enzyme (Basel) (1989)
    “…Dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2) catalyzes the rate-limiting reaction in the catabolism of endogenous uracil and thymine and exogenous…”
    Get more information
    Journal Article
  5. 5

    Circadian pattern of continuous FUDR infusion reduces toxicities by Roemeling, R V, Hrushesky, W J

    “…The toxicity and efficacy of at least a dozen of the most commonly used anticancer drugs vary predictably depending on when in the day they are given. In a…”
    Get more information
    Journal Article
  6. 6

    High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer by Hrushesky, W J, Roemeling, R V, Wood, P A, Langevin, T R, Lange, P, Fraley, E

    Published in Cancer treatment reports (01-10-1987)
    “…Thirteen patients with transitional cell carcinoma of the bladder received monthly circadian-timed doxorubicin and cisplatin chemotherapy immediately after…”
    Get more information
    Journal Article
  7. 7

    Mandibular myelosarcoma (chloroma): primary oral manifestation of promyelocytic leukemia by Reichart, P A, von Roemeling, R, Krech, R

    “…The case of a 35-year-old female patient with primary mandibular manifestation of myelosarcoma (chloroma) is reported. The clinical course and diagnostic and…”
    Get more information
    Journal Article
  8. 8

    Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences by Roemeling, R V, Olshefski, R, Langevin, T, Berestka, J, Reusch, J J, Reusch, J E, Lakatua, D, Wick, M R, Hrushesky, W J

    Published in Chronobiology international (1986)
    “…Cisplatin-induced mortality and nephrotoxicity are each predictably worse when the drug is given at certain points within the circadian schedule. Oral…”
    Get more information
    Journal Article
  9. 9
  10. 10
  11. 11

    Advanced transitional cell bladder cancer: a treatable disease by Roemeling, R V, Hrushesky, W J

    Published in Seminars in surgical oncology (1986)
    “…Although metastatic bladder cancer is difficult to treat effectively, chemotherapy combinations and schedules have emerged recently that can result in…”
    Get more information
    Journal Article
  12. 12
  13. 13
  14. 14